Tackling Barriers to Biomarker Testing to Personalize Immunotherapy for NSCLC

Tackling Barriers to Biomarker Testing to Personalize Immunotherapy for NSCLC

Continue to Course
Online Course | Specialties: Oncology, Pulmonary Disease
Released: 6/22/2022
Expires: 6/21/2023
Max Credits: 0.5

By clicking "Continue," you confirm that you have reviewed the CME information.

Continue Read Overview
Howard (Jack) West, MD
Associate Professor, Medical Oncology
Senior Medical Director, AccessHope
City of Hope Comprehensive Cancer Center
Duarte, CA

Sandip Patel, MD
Associate Professor, Medical Oncology
UC San Diego School of Medicine
Director, Clinical Trials Office
UCSD Moores Cancer Center
San Diego, CA

Activity Planners
Kia Jones, PhD
Clinical Content Manager
Baltimore, MD

Larissa Picard-Broussard
CME Coordinator
Baltimore, MD

Amy Sison
Director of CME
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM, CHCP
Associate Director, Education Quality and Compliance
East Lansing, MI

Anne Jacobson, MSPharm, CHCP
Cocoa Beach, FL

Learning Objectives
Upon completion, participants should be able to:
  • Integrate the personalized use of immunotherapies in NSCLC
  • Apply the comprehensive use of immunotherapy biomarkers to all eligible patients with NSCLC
  • Identify health disparities—and strategies to address them—regarding access to biomarker testing, immunotherapy, and clinical trials for NSCLC

Target Audience
This activity is intended for oncologists, pulmonologists, pathologists, surgeons, nurses, pharmacists, and other healthcare professionals involved in the diagnosis and care of patients with NSCLC.

Statement of Need
Immunotherapy has revolutionized the treatment of non–small cell lung cancer (NSCLC) for many patients with this condition, but not all patients with NSCLC are appropriate candidates for this treatment. Identifying those who are most likely to benefit is critical to the optimal use of these agents. Doing so requires testing for biomarkers, but practice data reveal relatively low rates of biomarker testing, particularly among minorities and in rural and underserved communities. Further hindering treatment with immunotherapy is low participation of racial minorities in clinical trials and low receipt among minorities of guideline-concordant care.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This nursing activity has been approved for up to 0.5 contact hour.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation
This CME/CE activity consists of a 0.5-credit Tweetorial. To receive credit, read the introductory CME/CE material, read the Tweetorial, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: June 22, 2022
Expiration Date: June 21, 2023
Estimated Time to Complete This Activity: 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all financial relationships with any ineligible company over the past 24 months. The ACCME deems financial relationships as relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and mitigate COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been mitigated through an established COI mitigation process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Howard (Jack) West, MD
Consulting fees/advisory boards: Amgen, AstraZeneca, EQRx, F. Hoffmann-La Roche Ltd., Genentech, Lilly, Merck & Co., Inc., Mirati Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited
Fees received for promotional/non-CME/CE activities: Amgen, AstraZeneca, Merck & Co., Inc., Mirati Therapeutics, Inc.

Sandip Patel, MD
Consulting fees/advisory boards: Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Genentech, Illumina, Lilly, Merck & Co., Inc., Pfizer, Inc., Rakuten Medical Inc., Tempus
Contracted research: Amgen, AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Fate Therapeutics, Genentech, Iovance Biotherapeutics, Inc., Lilly, MedImmune, Merck & Co. Inc., Pfizer, Inc., SQZ Biotechnologies Company

The writer, peer reviewers, and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For other questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email

System Requirements
For technical assistance, please refer to our Support Manual.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit:

Complimentary CME/CE
This activity is available free of charge to participants.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Merck & Co., Inc.


The following material has been developed to accompany this activity:

Understanding Biomarker-Based Care in NSCLC - English

Understanding Biomarker-Based Care in NSCLC - Spanish

Note: This material is not accredited for CME and, therefore, does not offer any CME/CE credit.


This ACCME- and ANCC-accredited Twitter Tweetorial presents a collection of individually threaded tweets focusing on the NSCLC immunotherapy biomarker testing landscape, relevant inequity data, practice pearls to reduce disparities, key takeaway messages, and relevant resources.

By clicking "Continue," you confirm that you have reviewed the CME information.


Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.